AKTX News & Events

Akari Therapeutics announced the acceptance of an Australian patent covering its core payload technology, and further expanding protection of its proprietary ADC platform. The accepted patent includes composition-of-matter claims covering proprietary analogs of Thailanstatin designed for use as cytotoxic ADC therapeutics. This patent contains broad claims covering the use of these proprietary splicing payloads with ADC linkers and may be used to target different proteins on the cancer cell. Akari's growing pipeline of novel ADCs including AKTX-101 and AKTX-102 all use the PH1 payload that is built around this novel IP.

Akari Therapeutics announced the presentation of positive preclinical data for its lead TROP2-targeting ADC, AKTX-101, at the American Association for Cancer Research, AACR, Annual Meeting 2026. Unlike current TROP2-targeting ADCs that use Topoisomerase I Inhibitor payloads, AKTX-101 has the potential to address resistance to Topoisomerase I Inh. ADCs and contribute to durable anti-tumor efficacy due to the payload's unique cytotoxic and immune-activating mechanisms of action. The preclinical data compares the performance of AKTX-101 versus TROP2 ADCs with Topoisomerase I Inh. payloads in the killing of different cancer types driven by different cancer genes. AKTX-101's ability to kill cancer cells at lower concentrations vs. TROP2 ADCs using Topoisomerase I Inh. payloads suggests that AKTX-101 is a more potent drug.